Study analysis · Food research international · 2025
A mushroom extract helped obese mice lose weight and improve blood sugar—by feeding their gut bacteria. But will it work in humans?
In obese mice, a fiber from Poria cocos improved weight, blood sugar, and fat metabolism by changing gut bacteria, but we don't know if it helps people.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done on mice, not people. It shows that a substance from a traditional Chinese medicine helped obese mice lose weight and use sugar better. But we can't say it will work the same way in humans—it's just a clue for scientists to study further.
What’s the bottom line?
Scientists fed mice a high-fat diet to make them obese, then gave some mice a fiber-like extract from Poria cocos (PCP). The PCP-treated mice gained less weight and had better blood sugar and fat levels. Their gut bacteria changed in ways that seemed helpful.
How strong is this study?
The scientists did a controlled experiment with mice, which is a good start. But they didn't say if the mice were randomly assigned to groups or if the researchers knew which treatment each mouse got, which can make results less trustworthy. Also, mice are not humans, so we need much more research before we know if this helps people.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal (mouse) study. Findings cannot establish cause-effect relationships in humans. Even within the animal model, randomization and blinding are not reported, limiting causal inference. Mechanistic pathways are inferred from associations and interventions but not definitively proven.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified. The study is funded by government grants, and authors are affiliated with academic institutions.
Funders
Conflict Details
National Natural Science Foundation of China Youth Program (82204748): Grant funding; listed as Funding acquisition in CRediT
Natural Science Key Project of Anhui Provincial Department: Grant funding; listed as Funding acquisition in CRediT
No competing interests statement was available in the article preview. All authors appear to be affiliated with academic or government research institutions. No industry funding detected.
Key takeaways
- 01
In obese mice, PCP for 8 weeks led to statistically significant reductions in body weight gain and epididymal fat mass, improved glucose tolerance and lipid metabolism, and higher levels of certain gut bacteria and short-chain fatty acids.
- 02
The absolute size of these effects was not reported; only significance was noted.
- 03
This is a mouse study, so no human absolute risk can be calculated.
- 04
It is unknown whether PCP would reduce weight or diabetes risk in people, and the study did not report how many cases per 1,000 could be helped or harmed.
Surprising findings
- The metabolic benefits of PCP were completely dependent on gut microbiota—antibiotics wiped out the effects.Many supplements are thought to act directly on host tissues, but this shows the gut bacteria are essential intermediaries.
- PCP increased specific bacteria (Lactobacillus, Allobaculum, Phascolarctobacterium) and SCFAs, which then activated FGF21 signaling.FGF21 is typically associated with fasting and liver metabolism, but here it's linked to gut-derived SCFAs from a dietary fiber. It's a novel connection.
- Despite the broad metabolic improvements, the study did not report any effect sizes or absolute risk reductions.In an era of open science, it's unusual to see a study report only p-values without effect sizes, making it hard to gauge practical significance.
Practical takeaways
If you're interested in gut health, consider eating a variety of fiber-rich foods that feed beneficial bacteria, like those increased in this study (e.g., Lactobacillus).
This study is in mice and used a specific polysaccharide extract, not whole mushrooms. Human trials are needed.
low confidenceDon't rush to buy Poria cocos supplements for weight loss based on this study.
No human evidence exists, and the study didn't report how much weight was lost.
high confidenceWhy this study matters
PCP reduced weight gain and fat mass in obese mice
After 8 weeks, mice on a high-fat diet given PCP had significantly lower body weight gain and epididymal fat mass compared to those on the high-fat diet alone. However, the study did not report the absolute size of these reductions—only that they were statistically significant (p-values reported, but no effect sizes).
Obesity is a major health issue, and finding natural compounds that could help is appealing. This study adds to the growing research on prebiotics for metabolic health.
Gut bacteria are required for the benefits
When researchers depleted gut bacteria with antibiotics, PCP's metabolic benefits disappeared. Fecal microbiota transplantation from PCP-treated mice to other mice transferred the benefits, showing the effects are microbiota-dependent.
This highlights the crucial role of gut bacteria in metabolism and suggests that prebiotics could be powerful. It also means that antibiotics might wipe out the benefits of such supplements.
Specific beneficial bacteria and SCFAs increased
PCP increased the abundance of Lactobacillus, Allobaculum, and Phascolarctobacterium, and raised levels of short-chain fatty acids (SCFAs) in the feces. SCFAs are thought to improve glucose and lipid metabolism.
These bacteria are often associated with health benefits, and SCFAs are a hot topic in microbiome research. It gives a concrete example of how a dietary fiber can shape the gut ecosystem.
Mechanism: FGF21/PI3K/AKT/GLUT4 signaling activated
PCP supplementation activated FGF21, PI3K, AKT, and GLUT4 in adipose tissue, which are key players in insulin sensitivity and glucose uptake. This suggests a molecular pathway for the metabolic improvements.
FGF21 is a hormone that regulates metabolism and is being studied for diabetes and obesity treatments. This study links it to gut-derived SCFAs from a dietary fiber.
No human data yet
This is a mouse study. No human trials have tested PCP for obesity or insulin resistance. The study also didn't report effect sizes, so we can't say how much PCP might help.
It's a reminder that promising animal studies don't always translate to humans. Many mouse findings fail in human trials.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists fed mice a high-fat diet to make them obese, then gave some mice a fiber-like extract from Poria cocos (PCP). The PCP-treated mice gained less weight and had better blood sugar and fat levels. Their gut bacteria changed in ways that seemed helpful.
Research results
In obese mice, PCP for 8 weeks led to statistically significant reductions in body weight gain and epididymal fat mass, improved glucose tolerance and lipid metabolism, and higher levels of certain gut bacteria and short-chain fatty acids. The absolute size of these effects was not reported; only significance was noted.
What this means - more context
This is a mouse study, so no human absolute risk can be calculated. It is unknown whether PCP would reduce weight or diabetes risk in people, and the study did not report how many cases per 1,000 could be helped or harmed.
Investigate whether Poria cocos polysaccharides (PCP) alleviate obesity-induced adipose tissue insulin resistance in high-fat diet (HFD)-induced obese mice and whether the effects depend on gut microbiota.
In HFD-fed obese mice, 8 weeks of PCP supplementation reduced weight gain and epididymal fat mass, improved glucose tolerance and lipid metabolism, alleviated adipocyte hypertrophy and colonic barrier damage, and modulated gut microbiota by increasing Lactobacillus, Allobaculum, Phascolarctobacterium and fecal short-chain fatty acids (SCFAs). These changes accompanied activation of FGF21/PI3K/AKT/GLUT4 signaling in adipose tissue. Antibiotic depletion and fecal microbiota transplantation indicated that PCP's metabolic benefits were gut microbiota-dependent in mice. No human data were reported.
Methods Used
High-fat diet-induced obese mice; 8-week PCP supplementation; control groups (normal diet, HFD); 16S rRNA sequencing; GC/MS for SCFAs; histological analysis; antibiotic depletion and fecal microbiota transplantation (FMT). Randomization and blinding were not specified.
Main Finding
In HFD-induced obese mice, PCP supplementation significantly reduced body weight gain and epididymal adipose tissue mass and improved glucose tolerance and lipid metabolism; absolute effect sizes were not reported. PCP increased beneficial gut bacteria and SCFAs and activated FGF21/PI3K/AKT/GLUT4 signaling. Antibiotic treatment diminished benefits and FMT transferred benefits, indicating gut microbiota-dependent effects in mice. No human absolute risk or effect size can be derived.
Confidence Level
Preclinical animal study; findings are statistically significant but lack effect sizes, confidence intervals, and absolute risk estimates. Results cannot be translated to human absolute risk. No human trials have tested PCP for adipose insulin resistance.
Study Flags
Red Flags
- •Preclinical mouse model; human relevance untested
- •No effect sizes, confidence intervals, or absolute risk reported
- •Causal role of gut microbiota established only in mice; human causality unknown
Surprising Findings
The metabolic benefits of PCP were completely dependent on gut microbiota—antibiotics wiped out the effects.
Many supplements are thought to act directly on host tissues, but this shows the gut bacteria are essential intermediaries.
Practical Takeaways
If you're interested in gut health, consider eating a variety of fiber-rich foods that feed beneficial bacteria, like those increased in this study (e.g., Lactobacillus).
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study was done on mice, not people. It shows that a substance from a traditional Chinese medicine helped obese mice lose weight and use sugar better. But we can't say it will work the same way in humans—it's just a clue for scientists to study further.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Controlled experimental design with HFD and PCP groups
- Use of antibiotic treatment and fecal microbiota transplantation (FMT) to test causality in mice
- Comprehensive assessment of metabolic, histological, and microbiome outcomes
Weaknesses
- Animal study, not human
- Randomization and blinding not reported
- Sample size not specified
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists fed mice a high-fat diet to make them obese, then gave some mice a fiber-like extract from Poria cocos (PCP). The PCP-treated mice gained less weight and had better blood sugar and fat levels. Their gut bacteria changed in ways that seemed helpful.
Research results
In obese mice, PCP for 8 weeks led to statistically significant reductions in body weight gain and epididymal fat mass, improved glucose tolerance and lipid metabolism, and higher levels of certain gut bacteria and short-chain fatty acids. The absolute size of these effects was not reported; only significance was noted.
What this means - more context
This is a mouse study, so no human absolute risk can be calculated. It is unknown whether PCP would reduce weight or diabetes risk in people, and the study did not report how many cases per 1,000 could be helped or harmed.
Investigate whether Poria cocos polysaccharides (PCP) alleviate obesity-induced adipose tissue insulin resistance in high-fat diet (HFD)-induced obese mice and whether the effects depend on gut microbiota.
In HFD-fed obese mice, 8 weeks of PCP supplementation reduced weight gain and epididymal fat mass, improved glucose tolerance and lipid metabolism, alleviated adipocyte hypertrophy and colonic barrier damage, and modulated gut microbiota by increasing Lactobacillus, Allobaculum, Phascolarctobacterium and fecal short-chain fatty acids (SCFAs). These changes accompanied activation of FGF21/PI3K/AKT/GLUT4 signaling in adipose tissue. Antibiotic depletion and fecal microbiota transplantation indicated that PCP's metabolic benefits were gut microbiota-dependent in mice. No human data were reported.
Methods Used
High-fat diet-induced obese mice; 8-week PCP supplementation; control groups (normal diet, HFD); 16S rRNA sequencing; GC/MS for SCFAs; histological analysis; antibiotic depletion and fecal microbiota transplantation (FMT). Randomization and blinding were not specified.
Main Finding
In HFD-induced obese mice, PCP supplementation significantly reduced body weight gain and epididymal adipose tissue mass and improved glucose tolerance and lipid metabolism; absolute effect sizes were not reported. PCP increased beneficial gut bacteria and SCFAs and activated FGF21/PI3K/AKT/GLUT4 signaling. Antibiotic treatment diminished benefits and FMT transferred benefits, indicating gut microbiota-dependent effects in mice. No human absolute risk or effect size can be derived.
Confidence Level
Preclinical animal study; findings are statistically significant but lack effect sizes, confidence intervals, and absolute risk estimates. Results cannot be translated to human absolute risk. No human trials have tested PCP for adipose insulin resistance.
Study Flags
Red Flags
- •Preclinical mouse model; human relevance untested
- •No effect sizes, confidence intervals, or absolute risk reported
- •Causal role of gut microbiota established only in mice; human causality unknown
Surprising Findings
The metabolic benefits of PCP were completely dependent on gut microbiota—antibiotics wiped out the effects.
Many supplements are thought to act directly on host tissues, but this shows the gut bacteria are essential intermediaries.
Practical Takeaways
If you're interested in gut health, consider eating a variety of fiber-rich foods that feed beneficial bacteria, like those increased in this study (e.g., Lactobacillus).
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study was done on mice, not people. It shows that a substance from a traditional Chinese medicine helped obese mice lose weight and use sugar better. But we can't say it will work the same way in humans—it's just a clue for scientists to study further.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Controlled experimental design with HFD and PCP groups
- Use of antibiotic treatment and fecal microbiota transplantation (FMT) to test causality in mice
- Comprehensive assessment of metabolic, histological, and microbiome outcomes
Weaknesses
- Animal study, not human
- Randomization and blinding not reported
- Sample size not specified
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a controlled experiment with mice, which is a good start. But they didn't say if the mice were randomly assigned to groups or if the researchers knew which treatment each mouse got, which can make results less trustworthy. Also, mice are not humans, so we need much more research before we know if this helps people.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal (mouse) study. Findings cannot establish cause-effect relationships in humans. Even within the animal model, randomization and blinding are not reported, limiting causal inference. Mechanistic pathways are inferred from associations and interventions but not definitively proven.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified. The study is funded by government grants, and authors are affiliated with academic institutions.
Funders
Conflict Details
National Natural Science Foundation of China Youth Program (82204748): Grant funding; listed as Funding acquisition in CRediT
Natural Science Key Project of Anhui Provincial Department: Grant funding; listed as Funding acquisition in CRediT
No competing interests statement was available in the article preview. All authors appear to be affiliated with academic or government research institutions. No industry funding detected.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
11 researchersIf this is your work, this is how we attribute it on Fit Body Science. Wen-Wen Liu is listed as the lead author.